Corporate Philanthropy

The Canadian Hemophilia Society is committed to improve the health and quality of life for all people with inherited bleeding disorders and ultimately to find a cure.

Working together with the corporate sector in Canada helps the Canadian Hemophilia Society (CHS) accomplish its mission and vision by extending our reach and reinforcing our messages. We seek contributions from like-minded corporations which support the CHS mission and vision, and which want to participate on an annual basis in providing support to general operational, research and program development initiatives that further the work of the CHS. Contributions are accepted from corporations and from corporate foundations, employee fund programs and employee generated activities.

Guiding Principles
The National Corporate Giving Program was created with a desire to...

• be open and transparent with our members, our sponsors, other stakeholders and with the public
• publicly recognize the contributions of our sponsors to the bleeding disorder community
• treat all our sponsors fairly
• maintain the independence of our organization in representing the needs of people with bleeding disorders.

BAXTER
As a subsidiary of Baxter International Inc., Baxter Corporation (Canada) develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, and other chronic and acute medical conditions.  As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.
 

Baxter Hemophilia Research and Development
Baxter is a global leader in hemophilia therapy, with innovations that span half a century. Through its own scientific expertise and strategic collaborations, Baxter is applying novel technologies that will pioneer the next generations of hemophilia therapies. The company is investigating ways to provide less invasive dosing techniques, longer acting therapies that require less frequent infusions, and reduce the potential for inhibitor formation to help improve the lives of people with hemophilia. Baxter has the following items available upon request from your local Hemophilia Treatment Centre:

•    DVD series – Powerful and user-friendly tools that display school educators, nurses, and parents discussing the issues surrounding hemophilia and demonstrating the various strategies to provide for a bright future. The following DVD’s are available:

1. Hemophilia: Healthy Living
2. Hemophilia:  Teaching the Educators
3. The Hemophilia Diagnosis: The Extended Family
4. In Full Motion: Protecting Your Healthy Joints

•    Children’s book – Just a Boy is a tale written by Ziva Mann about an energetic  boy with hemophilia. The notes at the back of the book suggest ways to help your child cope with minor pain such as needle sticks and suggest questions to encourage your child to talk to you about his feelings.

•    Planning Travel: A Guide for People with Bleeding Disorders – This travel brochure helps people with bleeding disorders to best prepare for travel. It acts as a checklist for people with bleeding disorders and highlights specific aspects of travel planning that patients should consider.

To learn more about Baxter Corporation (Canada)
please visit our Web site. - Baxter


BAYER HEALTHCARE PHARMACEUTICALS
Hematology / Cardiology
Bayer HealthCare Pharmaceuticals is among the top five specialty pharmaceutical companies in Canada and is a leader in the field of hematology and cardiology. For more than 20 years, Bayer HealthCare Pharmaceuticals, together with its international affiliates, has been extending and enhancing the lives of patients with chronic blood coagulation disorders such as hemophilia through the development of innovative and safe treatment options.

Although hemophilia remains incurable to this day, Bayer is one of the world’s main suppliers of products to treat this hereditary disease. We recognize the great medical need for therapies that can improve the quality of life. Our focus of research in hemophilia is to develop a novel therapy that lasts longer in the body in such a way that it need not be injected so frequently.

We are deeply committed to providing Canadians with the best medicine and continue to invest in the research and development of innovative pharmaceutical products to improve the lives of patients.

For more information on Bayer HealthCare Pharmaceuticals and its commitment to hematology and cardiology, please visit our Web site. - Bayer

CSL BEHRING
As a global leader in the plasma protein biotherapeutics industry, we research, develop, manufacture and market biotherapies used to treat serious often life threatening diseases.

CSL Behring Canada is proud of our heritage that has delivered biotherapies for life for more than a century. We are committed to providing safe and effective biotherapies to Canadians, now and in the future.

CSL Behring is passionate about meeting the needs of our customers. CSL Behring is very proud to be part of the CHS Benefactors Club, and to support the CHS with the great work they do. We look forward to working with the CHS.

For more information on CSL Behring, please visit our Web site. - CSL Behring


NOVO NORDISK
Novo Nordisk is dedicated to changing possibilities for people with hemophilia and inhibitors.  We are focused on improving treatment options, providing better access to care and following through our commitment to understanding the needs of people with hemophilia.

Novo Nordisk began research and development in hemophilia more than 20 years ago. As a global leader in hemophilia care, Novo Nordisk continues to redefine treatment and develop safe, effective and more convenient approaches; placing control back in the hands of people
with hemophilia, and helping them to lead full and active lives.

For more information on Novo Nordisk, please visit our Web site. - Novo Nordisk